EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy.
Iason PsilopatisEleni Souferi-ChronopoulouKleio VrettouConstantinos TroungosStamatios TheocharisPublished in: International journal of molecular sciences (2022)
Breast cancer (BC) is the most common malignant tumor in women. Erythropoietin-producing hepatocellular receptors (EPHs), receptor tyrosine kinases binding the membrane-bound proteins ephrins, are differentially expressed in BC, and correlate with carcinogenesis and tumor progression. With a view to examining available therapeutics targeting the EPH/ephrin system in BC, a literature review was conducted, using the MEDLINE, LIVIVO, and Google Scholar databases. EPHA2 is the most studied EPH/ephrin target in BC treatment. The targeting of EPHA2, EPHA10, EPHB4, ephrin-A2, ephrin-A4, as well as ephrin-B2 in BC cells or xenograft models is associated with apoptosis induction, tumor regression, anticancer immune response activation, and impaired cell motility. In conclusion, EPHs/ephrins seem to represent promising future treatment targets in BC.
Keyphrases
- cancer therapy
- immune response
- induced apoptosis
- cell death
- cell cycle arrest
- stem cells
- endoplasmic reticulum stress
- transcription factor
- machine learning
- inflammatory response
- type diabetes
- dendritic cells
- signaling pathway
- pregnant women
- skeletal muscle
- case report
- insulin resistance
- recombinant human
- pi k akt
- cervical cancer screening
- childhood cancer